Delpor announced topline results of its DLP-114 Phase 1b/2a clinical study during which schizophrenia patients received treatment for up...
Read more
MemVerge and Sentieon announced a collaboration to accelerate next-generation sequencing (NGS) in the public cloud. MemVerge and Sentieon integrated...
Read more
Behavioral Signals has announced its work in the federal marketplace. “AI is ushering in a profound transformation in the...
Read more
PteroDynamics announced a successful demonstration of the advanced capabilities of its automated Transwing vertical takeoff and landing UAS at the...
Read more
The Retinal Degeneration Fund – the venture arm of the Foundation Fighting Blindness aimed at rapidly driving research to...
Read more
The Gut Microbiome May Unlock New Treatment Paradigms For Neurological Diseases – Axial Therapeutics
Autistic children have long been known to have differences in their gut microbiota and as a result are more...
Read more
Axial Therapeutics announced completion of enrollment in the TAPESTRY Autism Study, the Phase 2b clinical trial of its lead...
Read more
Behavioral Signals announced that it has been recognized by Gartner in Six (6) Hype Cycle 2023 reports, in addition...
Read more
MemVerge® introduced QEMU-based CXL Flight Simulator, a virtual CXL hardware environment that allows software engineers to kick off development without...
Read more
Actuate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for elraglusib...
Read more